Faron, etusivu

releases and publications

Faron to Host KOL Webinar on the Potential of Clever-1 Receptor as a Target for Macrophage-Guided Immunotherapy on July 19, 2021

Updated corporate presentation

Regulatory

Bexmarilimab granted key US patent

Regulatory

Bexmarilimab results published in CCR

Regulatory

Bexmarilimab shows promising anti-tumour activity

Regulatory

US rights to patent related to Traumakine

Regulatory

Holding(s) in Company

Shareholder announcement Regulatory

Grant of options

Insider Transaction Regulatory

Board Change

Regulatory

Result of AGM

Regulatory
PreviousNext
Back to top